BioNumerik Pharmaceuticals

BioNumerik Pharmaceuticals, Inc. is dedicated to the discovery, development, and commercialization of drugs aimed at helping treat cancer. The company’s two oncology drug candidates, Tavocept and BNP1350, are in the late stages of clinical development.